Compare GIC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIC | EVO |
|---|---|---|
| Founded | 1949 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1996 | N/A |
| Metric | GIC | EVO |
|---|---|---|
| Price | $30.43 | $2.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 93.8K | 45.0K |
| Earning Date | 05-05-2026 | 04-08-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | ★ 17.09 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $1,379,100,000.00 | N/A |
| Revenue This Year | $5.72 | $1.37 |
| Revenue Next Year | $4.60 | $10.05 |
| P/E Ratio | $72.88 | ★ N/A |
| Revenue Growth | ★ 4.80 | N/A |
| 52 Week Low | $26.07 | $2.31 |
| 52 Week High | $38.53 | $4.42 |
| Indicator | GIC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 49.58 | 47.56 |
| Support Level | $29.22 | $2.88 |
| Resistance Level | $32.16 | $3.82 |
| Average True Range (ATR) | 0.68 | 0.06 |
| MACD | 0.25 | 0.01 |
| Stochastic Oscillator | 83.62 | 56.12 |
Global Industrial Co is a value-added industrial distributor. The company distributes a wide range of industrial and maintenance, repair, and operations (MRO) products to customers across North America, including storage and shelving, safety and security, carts and trucks, HVAC and fans, furniture and decor, material handling, janitorial and facility maintenance, workbenches and shop desks, tools and instruments, plumbing and pumps, office and school supplies, packaging and shipping, lighting and electrical, food service and retail, medical and laboratory, motors and power transmission, building supplies, machining, fasteners and hardware, vehicle maintenance, and raw material.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.